Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Nizar El Khalili

Psychiatry Lafayette, IN Medical Doctor

NPI 1861429714 CMS profile 758107

3660 Rome Dr, Lafayette, IN 47905

Open in the dashboard

General payments

$19,266

169 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Nizar El Khalili of Lafayette, IN is reported in the CMS Open Payments database as having received $19,266 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $34 2
2021 General $639 47
2020 General $5,916 20
2019 General $12,678 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nizar El Khalili
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Nizar El Khalili were reported at $0. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Nizar El Khalili Psychiatry median Middle half National median
2019 $12,678 $184 $59–$605 $163
2020 $5,916 $119 $36–$372 $114
2021 $639 $143 $43–$576 $132
2022 $34 $153 $50–$590 $149
2023 $0 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $0 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Janssen Pharmaceuticals, Inc $17,813 71 payments
  2. Lundbeck LLC $272 19 payments
  3. Otsuka America Pharmaceutical, Inc. $210 14 payments
  4. AbbVie, Inc. $169 15 payments
  5. Alkermes, Inc. $118 5 payments
  6. Teva Pharmaceuticals USA, Inc. $76 5 payments
  7. Shire North American Group Inc $75 5 payments
  8. Avanir Pharmaceuticals, Inc. $71 5 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $69 4 payments
  10. Allergan Inc. $67 5 payments
  11. Other $328 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,250 10 payments
  2. Food and Beverage $2,530 151 payments
  3. Travel and Lodging $2,466 4 payments
  4. Education $21 4 payments
Products named General payments · program years 2019–2022
  1. SPRAVATO $17,730 64 payments
  2. INVEGA SUSTENNA $269 19 payments
  3. VRAYLAR $169 15 payments
  4. BRINTELLIX $151 10 payments
  5. REXULTI $142 10 payments
  6. ABILIFY MAINTENA $110 7 payments
  7. ARISTADA INITIO $94 4 payments
  8. ARISTADA Cns $94 4 payments
  9. ARISTADA Cns $94 4 payments
  10. ARISTADA Cns $94 4 payments
  11. Other $1,074 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record